Merck & Co. (NYSE: MRK) shares jumped more than 8% on Friday, after the company released an update regarding its experimental Covid-19 antiviral oral drug molnupiravir. The interim analysis from the Phase 3 trial found Molnupiravir may prevent the chances of hospitalization or death from COVID-19 by 50% among people who are at high risk …
Merck stock gains on COVID pill hopes – is MRK stock a game changer? Read More »
Ocugen Inc (NASDAQ: OCGN) is a US based bio-pharma which has primarily focused its research on developing a cure for blindness disease. In 2020, Ocugen shifted its efforts to distribute a COVID-19 vaccine with Indian partner Bharat Biotech. Ocugen’s CEO Shankar Musunuri made it clear that the company strategises to disrupt the current COVID-19 vaccine …
Ocugen Stock Forecast – what can investors expect over the next 5 years? Read More »
Soaring Eagle Acquisition Corp. (NASDAQ:SRNG) is set to merge with bio tech company Ginkgo Bioworks in a $15 Billion deal. The mammoth deal is expected to provide the biotech company $2.5 Billion in primary cash proceeds to fund future growth within multiple industries. Ginkgo Bioworks program living cells to utilise their potential across a vast …
SRNG is set to merge with Ginkgo Bioworks – here’s what you need to know Read More »
To say Moderna (NASDAQ:MRNA) has had a brilliant year trading on Wallstreet would be an understatement. The COVID-19 vaccine candidate has provided investors immense returns over the past 12-18 months gaining 333% YTD. Moderna’s strong revenue boost in 2021 has been derived from the overall depth of the COVID-19 vaccine market, which is expected to …
Moderna stock forecast – Where will Moderna be in 2025? Read More »
Cassava Sciences Inc (NASDAQ:SAVA) stock has experienced a strong bullish run over the past month, gaining 51%. Investors are awaiting Cassava’s clinical-trial data to be presented at the Alzheimer’s Association International Conference (AAIC) on July 29. The data is from Cassava’s leading candidate Sumifilam. The drug aims to treat Alzheimer’s by reducing neuro-degeneration and neuroinflammation. …
Analysts see upside in Cassava Sciences stock after its bullish run Read More »
Tempest Therapeutics (NASDAQ:TPST) is gaining momentum this week after H.C Wainwright listed a $51 price target on the stock. The stock is running strong after the completion of the Millendo Therapeutics merger. TPST has gained 108% over the past week of trading, which is driving large amounts of interest in the stock. Tempest is a …
Is TPST stock a buy after H.C. Wainwright sets a $51 price target? Read More »
Clover Health Investments Corp (NASDAQ: CLOV) has struggled over the past month, declining by 33%. Despite the recent decline, Clover is the fastest growing Medicare Advantage insurer in the United States. The company serves more than 66,300 members all in the United States. Clover Health stock initially caught the attention of investors after SPAC Billionaire Chamath …
Clover Health stock forecast (NASDAQ:CLOV) – is there upside potential? Read More »
Ocugen Inc (NASDAQ: OCGN) is a US based bio-pharma which has focused on developing a cure for blindness disease. However, the company has since shifted its efforts to develop a COVID-19 vaccine with partner Bharat Biotech. Ocugen’s CEO Shankar Musunuri has made it clear the company strategises to disrupt the current COVID-19 vaccine market with …
Ocugen stock forecast (NASDAQ:OCGN) – what investors need to know Read More »
Sorrento Therapeutics Inc (NASDAQ: SRNE) has recaptured the attention of Wallstreet after the company obtained authorisation to commence Phase 2 trials for its COVID-19 experimental treatment COVI-DROPS. COVIDROPS is a intranasal formulation of Sorrento’s COVI-AMG™ neutralizing antibody that aims to boost immunity by blocking the infection and spread of the virus. Sorrento holds a dynamic …
Sorrento Therapeutics (NASDAQ:SRNE) stock gains bullish momentum Read More »
Novavax, Inc.(NASDAQ: NVAX) has seen an incredible year in stock price growth, increasing 307% over the past 12 months. The companies COVID-19 vaccine saw the market rally behind NVAX, posting a 52 week high in February of $331.68. The company announced yesterday that their COVID-19 vaccine NVX-CoV2373 demonstrated 100% protection against moderate and severe disease …
Novavax stock forecast (NASDAQ: NVAX) – are investors buying now? Read More »